Rational approaches to treatment duration with immunotherapy for kidney cancer

A recent review of the use of immune checkpoint inhibitors for the treatment of metastatic renal cell carcinoma (RCC) was published in European Urology Focus this month. The use of immune checkpoint inhibitors has revolutionised the treatment of metastatic RCC over recent years. However, the appropriate duration of treatment with immune checkpoint inhibitors, such as […]

read more

Individualised treatment plans improve outcomes for kidney cancer

Over the past couple of years there have been several approvals of new treatments and drug combinations for advanced/metastatic renal cell carcinoma (RCC) resulting in treatment plans that are tailored for the individual patient. Recent advances in the treatment of advanced/metastatic RCC include cabozantinib, nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib. Dr Ajjai Shivaram Alva, associate professor at […]

read more

ESMO 2019: Results from TITAN-RCC tailored immunotherapy clinical trial

Results from the TITAN-RCC clinical trial to assess tailored immunotherapy for patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. TITAN-RCC is a large phase 2 study investigating tailored immunotherapy for people with advanced RCC. Patients started with nivolumab monotherapy. The […]

read more
Showing all 3 results